Sernova receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A program from FDA.
Sernova Corp., a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for the company’s Hemophilia A program. The FDA…
